On August 3, 2023, Alan Huang, Ph.D., Tango Therapeutics, Inc. Chief Scientific Officer, notified the Company that he intends to transition out of his role as Chief Scientific Officer. For the period from August 7, 2023 to October 6, 2023, Dr. Huang will continue to serve in his capacity as the Company's Chief Scientific Officer, and will be dedicating 60% of his time to his duties as the Company's Chief Scientific Officer. Following October 6, 2023, Dr. Huang will serve as a consultant for the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.31 USD | +2.89% | -7.35% | -26.16% |
05-08 | Tango Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-04 | British billionaire Joe Lewis fined $5 million by US judge for insider trading | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.16% | 781M | |
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+45.09% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |
- Stock Market
- Equities
- TNGX Stock
- News Tango Therapeutics, Inc.
- Tango Therapeutics, Inc. Announces Alan Huang, Ph.D., the Company's Chief Scientific Officer, Intends to Transition Out of His Role as Chief Scientific Officer